Ascentage Pharma Group International (HKG:6855)
45.96
+3.20 (7.48%)
At close: Mar 27, 2026
HKG:6855 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,470 | 1,261 | 1,094 | 1,492 | 1,744 |
Short-Term Investments | - | 5.37 | 6.56 | 11.91 | 4.14 |
Cash & Short-Term Investments | 2,470 | 1,267 | 1,100 | 1,504 | 1,748 |
Cash Growth | 95.02% | 15.10% | -26.84% | -13.95% | 70.13% |
Accounts Receivable | 252.94 | 83.14 | 145.89 | 54.36 | 53.97 |
Other Receivables | - | 15.93 | 17.65 | 7.13 | 22.48 |
Receivables | 252.94 | 99.07 | 163.54 | 61.49 | 76.45 |
Inventory | 28.62 | 6.6 | 16.17 | 9.45 | 3.93 |
Other Current Assets | 192.53 | 101.91 | 64.08 | 61.41 | 56.93 |
Total Current Assets | 2,944 | 1,474 | 1,344 | 1,636 | 1,885 |
Property, Plant & Equipment | 829.06 | 905.56 | 957.07 | 648.72 | 844.37 |
Long-Term Investments | 37.03 | 33.86 | 18.95 | 18.53 | 27.85 |
Goodwill | 24.69 | 24.69 | 24.69 | 24.69 | 24.69 |
Other Intangible Assets | 65.94 | 76 | 85.45 | 84.3 | 60.41 |
Long-Term Deferred Tax Assets | 31.96 | 44.24 | 59.84 | 54.29 | 51.65 |
Long-Term Deferred Charges | - | 30.53 | - | - | - |
Other Long-Term Assets | 30.73 | 28.77 | 10.22 | 363.23 | 45.81 |
Total Assets | 3,964 | 2,618 | 2,500 | 2,830 | 2,940 |
Accounts Payable | 106.74 | 91.97 | 72.45 | 95.56 | 70.86 |
Accrued Expenses | - | 153.33 | 125.68 | 120.65 | 75.32 |
Short-Term Debt | 1,222 | 290 | 120 | 139.9 | - |
Current Portion of Long-Term Debt | - | 479.62 | 486.65 | 370.41 | 39.8 |
Current Portion of Leases | - | 9.44 | 9.76 | 8.08 | 9.65 |
Current Unearned Revenue | 37.49 | 54.09 | 38.41 | 24.35 | 24.36 |
Other Current Liabilities | 276.67 | 88.17 | 81.24 | 122.21 | 141.12 |
Total Current Liabilities | 1,643 | 1,167 | 934.17 | 881.15 | 361.11 |
Long-Term Debt | 757.24 | 868.64 | 1,166 | 1,265 | 1,027 |
Long-Term Leases | - | 20.79 | 12.92 | 9.14 | 8.25 |
Long-Term Unearned Revenue | 216.72 | 275.96 | 287.55 | 218.63 | 243.28 |
Long-Term Deferred Tax Liabilities | - | 5.37 | 10.55 | 12.15 | 13.75 |
Other Long-Term Liabilities | 12.03 | 6.27 | 18.3 | 35.33 | 52.34 |
Total Liabilities | 2,629 | 2,344 | 2,430 | 2,422 | 1,705 |
Common Stock | 0.26 | 0.21 | 0.2 | 0.18 | 0.18 |
Additional Paid-In Capital | - | 6,545 | 5,951 | 5,393 | 5,342 |
Retained Earnings | - | -5,771 | -5,365 | -4,439 | -3,557 |
Treasury Stock | -2.96 | -0.01 | -21.35 | -26.55 | -0 |
Comprehensive Income & Other | 1,327 | -510.59 | -504.46 | -518.51 | -550.95 |
Total Common Equity | 1,324 | 264.19 | 60.42 | 408.66 | 1,235 |
Minority Interest | 9.75 | 9.97 | 10.22 | - | - |
Shareholders' Equity | 1,334 | 274.16 | 70.63 | 408.66 | 1,235 |
Total Liabilities & Equity | 3,964 | 2,618 | 2,500 | 2,830 | 2,940 |
Total Debt | 1,980 | 1,668 | 1,796 | 1,793 | 1,084 |
Net Cash (Debt) | 490.37 | -401.92 | -695.21 | -288.58 | 663.68 |
Net Cash Growth | - | - | - | - | 33.34% |
Net Cash Per Share | 1.38 | -1.33 | -2.46 | -1.09 | 2.61 |
Filing Date Shares Outstanding | 370.6 | 312.37 | 290.05 | 259.91 | 257.61 |
Total Common Shares Outstanding | 370.6 | 312.37 | 290.05 | 259.91 | 257.61 |
Working Capital | 1,301 | 307.55 | 410.01 | 755.34 | 1,524 |
Book Value Per Share | 3.57 | 0.85 | 0.21 | 1.57 | 4.79 |
Tangible Book Value | 1,234 | 163.5 | -49.72 | 299.66 | 1,150 |
Tangible Book Value Per Share | 3.33 | 0.52 | -0.17 | 1.15 | 4.46 |
Buildings | - | 836.02 | 834.91 | 470.22 | 406.95 |
Machinery | - | 183.34 | 179.87 | 155.21 | 60.98 |
Construction In Progress | - | 7.29 | 12.65 | 39.49 | 362.86 |
Leasehold Improvements | - | 44.24 | 29.22 | 7.74 | 8.14 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.